Cantex is developing Azeliragon for the treatment of cancer and inflammatory lung diseases.
Azeliragon
- Azeliragon, is an oral, small molecule, in phase 2 and phase 3 clinical trials, administered once-daily, that inhibits RAGE interactions with its diverse ligands, in the cancer and lung Activation of RAGE by these ligands stimulates cancer and its progression and metastasis and resistance to cancer treatment and plays an integral role in the initiation and progression of severe pneumonia, asthma and COPD.
- Azeliragon was licensed in mid 2021 from vTv Therapeutics Inc. (NASDAQ:VTVT) and was originally in development by vTv for Alzheimer’s disease. Clinical safety data, involving over 2000 patients treated for up to 18 months, indicated a high level of safety and tolerability of azeliragon.
- There has been extensive demonstration of pre-clinical efficacy of RAGE inhibition in animal models of several cancers, including pancreatic cancer, breast cancer, brain metastasis and glioblastoma, as well as other serious diseases including severe pneumonia, and asthma.
- Azeliragon is in clinical development for the treatment of pancreatic cancer, breast cancer, brain metastasis and glioblastoma, and severe pneumonia.. Azeliragon has several issued patents including composition of matter patents that protect azeliragon from generic competition until October 2039
- Azeliragon also has orphan drug designation for the treatment of pancreatic cancer, brain metastasis from breast cancer, and glioblastoma, conferring seven years of protection for those indications from generic competition.
